dc.contributor.author | Lund-Iversen, Marius | |
dc.contributor.author | Scott, Helge | |
dc.contributor.author | Strøm, Erik Heyerdahl | |
dc.contributor.author | Theiss, Noah | |
dc.contributor.author | Brustugun, Odd Terje | |
dc.contributor.author | Grønberg, Bjørn Henning | |
dc.date.accessioned | 2018-09-10T14:13:12Z | |
dc.date.available | 2018-09-10T14:13:12Z | |
dc.date.created | 2018-07-05T14:56:51Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Anticancer Research. 2018, 38 (4), 2261-2269. | nb_NO |
dc.identifier.issn | 0250-7005 | |
dc.identifier.uri | http://hdl.handle.net/11250/2561844 | |
dc.description.abstract | Background/Aim: The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated whether this observation could be explained by the expression of estrogen receptor-alpha (ER-α) in tumor tissue.
Materials and Methods: Archived, formalin fixed, paraffin embedded tumor tissue samples were retrospectively analyzed for nuclear expression of ER-α with immunohistochemistry.
Results: Biopsies from 222 patients were analyzed. Twenty-three percent were ER-α positive. Fifty-four percent of the patients were men and 46% of the tumors were adenocarcinomas. One hundred-nine (49%) patients received pemetrexed and carboplatin and 113 (51%) received gemcitabine and carboplatin. Females with ER-α positive tumors who received PC had a substantial survival benefit over all other groups (20 vs. 4.6 months; p=0.003).
Conclusion: ER-α is an independent prognostic factor in advanced NSCLC and might also be a predictive factor for response to pemetrexed/carboplatin in women. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | International Institute of Anticancer Research (IIAR) | nb_NO |
dc.title | Expression of estrogen receptor-α and survival in advanced-stage non-small cell lung cancer | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.source.pagenumber | 2261-2269 | nb_NO |
dc.source.volume | 38 | nb_NO |
dc.source.journal | Anticancer Research | nb_NO |
dc.source.issue | 4 | nb_NO |
dc.identifier.doi | 10.21873/anticanres.12470 | |
dc.identifier.cristin | 1595958 | |
dc.description.localcode | This article will not be available due to copyright restrictions (c) 2018 by International Institute of Anticancer Research (IIAR) | nb_NO |
cristin.unitcode | 194,65,15,0 | |
cristin.unitname | Institutt for klinisk og molekylær medisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |